M C Turner1,2, D Becerra3, Z Sun3, J Watson3, K Leung3, J Migaly3, C R Mantyh3, D G Blazer3. 1. Department of Surgery, Duke University Health Systems, Durham, NC, 27710, USA. megan.turner@duke.edu. 2. Duke University Medical Center, Box 3443, Durham, NC, 27710, USA. megan.turner@duke.edu. 3. Department of Surgery, Duke University Health Systems, Durham, NC, 27710, USA.
Abstract
BACKGROUND: Due to conflicting study results on the effect of laterality on overall survival in primary colon cancers, we sought to examine the impact of left compared to right-sided primary tumors on overall survival for stage I-III colon cancer using the largest dataset to date. METHODS: The 2006-2013 NCDB was queried for patients with single primary, stage I-III colon adenocarcinoma and grouped by stage and tumor location. RESULTS: For stage I-II tumors, 114,839 patients had resection (62% right:38% left). After adjustment, patients with right-sided tumors had superior survival ([HR right as reference]: 1.13, 95% CI 1.09-1.17, p < 0.001). For stage III tumors, 71,024 patients had resection, (59% right:41% left). After adjustment, patients with left-sided tumors had superior survival with chemotherapy (HR 0.85, p < 0.001) and no difference in survival without chemotherapy (HR 0.97, p = 0.18). CONCLUSIONS: The side of the primary tumor impacts overall survival across stages for colon adenocarcinoma. Patients with right-sided tumors have superior survival for stage I-II disease while patients with left-sided stage III disease demonstrate a survival advantage, suggesting an opportunity for investigators to use sidedness as a surrogate for prognosis and chemoresponsiveness.
BACKGROUND: Due to conflicting study results on the effect of laterality on overall survival in primary colon cancers, we sought to examine the impact of left compared to right-sided primary tumors on overall survival for stage I-III colon cancer using the largest dataset to date. METHODS: The 2006-2013 NCDB was queried for patients with single primary, stage I-III colon adenocarcinoma and grouped by stage and tumor location. RESULTS: For stage I-II tumors, 114,839 patients had resection (62% right:38% left). After adjustment, patients with right-sided tumors had superior survival ([HR right as reference]: 1.13, 95% CI 1.09-1.17, p < 0.001). For stage III tumors, 71,024 patients had resection, (59% right:41% left). After adjustment, patients with left-sided tumors had superior survival with chemotherapy (HR 0.85, p < 0.001) and no difference in survival without chemotherapy (HR 0.97, p = 0.18). CONCLUSIONS: The side of the primary tumor impacts overall survival across stages for colon adenocarcinoma. Patients with right-sided tumors have superior survival for stage I-II disease while patients with left-sided stage III disease demonstrate a survival advantage, suggesting an opportunity for investigators to use sidedness as a surrogate for prognosis and chemoresponsiveness.
Entities:
Keywords:
Chemotherapy; Colon adenocarcinoma; Left versus right; Overall survival; Sidedness; Surgery
Authors: K Birkenkamp-Demtroder; S H Olesen; F B Sørensen; S Laurberg; P Laiho; L A Aaltonen; T F Orntoft Journal: Gut Date: 2005-03 Impact factor: 23.059
Authors: Nancy N Baxter; Meredith A Goldwasser; Lawrence F Paszat; Refik Saskin; David R Urbach; Linda Rabeneck Journal: Ann Intern Med Date: 2008-12-15 Impact factor: 25.391
Authors: Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger Journal: N Engl J Med Date: 2003-07-17 Impact factor: 91.245
Authors: Oleg K Glebov; Luz M Rodriguez; Kenneth Nakahara; Jean Jenkins; Janet Cliatt; Casey-Jo Humbyrd; John DeNobile; Peter Soballe; Richard Simon; George Wright; Patrick Lynch; Sherri Patterson; Henry Lynch; Steven Gallinger; Aby Buchbinder; Gary Gordon; Ernest Hawk; Ilan R Kirsch Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-08 Impact factor: 4.254
Authors: Robert A Meguid; Mark B Slidell; Christopher L Wolfgang; David C Chang; Nita Ahuja Journal: Ann Surg Oncol Date: 2008-07-12 Impact factor: 5.344